Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 1.00 |
| ▸ | DRD1 | P21728 | 11/20 | 1.00 |
| ▸ | DRD5 | P21918 | 1/20 | 0.92 |
| ▸ | DRD3 | P35462 | 1/20 | 0.92 |
| ▸ | RAD52 | P43351 | 1/20 | 0.84 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29999626 | 1.00 | DRD2 (1.00) | DRD2DRD1DRD5DRD3RAD52 | |
| Discretine SCHEMBL29408007 | 1.00 | DRD2 (1.00) | DRD2DRD1DRD5DRD3RAD52 | |
| SCHEMBL30473248 | 1.00 | DRD2 (1.00) | DRD2DRD1DRD5DRD3RAD52 | |
| SCHEMBL910400 | 1.00 | DRD2 (1.00) | DRD2DRD1DRD5DRD3RAD52 | |
| SCHEMBL910848 | 1.00 | DRD2 (1.00) | DRD2DRD1DRD5DRD3RAD52 | |
| SCHEMBL30473250 | 0.96 | DRD2 (1.00) | DRD2DRD1DRD5DRD3RAD52 | |
| SCHEMBL14703834 | 0.96 | DRD1 (1.00) | DRD2DRD1DRD5DRD3RAD52 | |
| SCHEMBL14703833 | 0.96 | DRD1 (1.00) | DRD2DRD1DRD5DRD3RAD52 | |
| Coreximine SCHEMBL30473249 | 0.96 | DRD1 (1.00) | DRD2DRD1DRD5DRD3RAD52 | |
| SCHEMBL14703870 | 0.96 | DRD1 (1.00) | DRD2DRD1DRD5DRD3RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | LIPC, FABP1, CPT1A | DRD2 4557/4885DRD1 4727/4885DRD5 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.